Skip to main content
S&P 5007,628.11-1.20%DOW52,205.98-0.26%NASDAQ25,593.82-2.26%BTC$77,064.00-3.57%ETH$2,222.33-4.04%GOLD$3,940.10-2.26%OIL$103.80+1.76%
Smart Investors Daily
SID Premium
CM

NASDAQ · CMPX

Compass Therapeutics, Inc.

Healthcare · Biotechnology

$0.76

Down-$0.00 (-0.54%)

Updated Oct 30, 2026, 12:01 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
745.36M
P/E ratio
-11.33
Dividend yield
0.00%
52-week range
$0.73 – $6.88
Volume
2.03M
Avg. volume
1.88M

Price performance · CMPX

CMPX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

CMPX closed at $0.76 after 21 trading sessions, down 16.08% for the selected period.

Last close
$0.76
Period change
-16.08%
Period low
$0.75
Period high
$1.02
Daily close
View OHLC price history
CMPX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$0.7798$0.8099$0.7509$0.75622.03M
Oct 28, 2026$0.7453$0.7751$0.7302$0.76031.8M
Oct 27, 2026$0.7519$0.785$0.73$0.74742.21M
Oct 26, 2026$0.75$0.7925$0.7409$0.74722.24M
Oct 23, 2026$0.7805$0.8069$0.7501$0.7612.13M
Oct 22, 2026$0.8129$0.8405$0.7801$0.80152.17M
Oct 21, 2026$0.822$0.8449$0.8079$0.81451.54M
Oct 20, 2026$0.8331$0.8679$0.8221$0.83331.88M
Oct 19, 2026$0.8699$0.8894$0.8259$0.8353.12M
Oct 16, 2026$0.90$0.9092$0.86$0.862.04M
Oct 15, 2026$0.86$0.9046$0.8504$0.89673.34M
Oct 14, 2026$0.831$0.8818$0.8217$0.8794.97M
Oct 13, 2026$0.9308$0.9375$0.8536$0.8573.8M
Oct 12, 2026$0.99$0.99$0.9202$0.93754.44M
Oct 9, 2026$0.9932$1.05$0.9779$0.9933.67M
Oct 8, 2026$1.01$1.01$0.9573$0.98347.04M
Oct 7, 2026$0.98$1.055$0.965$1.022.79M
Oct 6, 2026$0.99$1.02$0.94$0.99817.29M
Oct 5, 2026$0.9099$0.9999$0.89$0.960615.83M
Oct 2, 2026$0.9401$0.9798$0.8294$0.856720.75M
Oct 1, 2026$1.03$1.055$0.9009$0.901110.07M

Latest CMPX news

The latest Smart Investors Daily articles mentioning CMPX.

Stock researchCompany · Overview

CMPX research

Overview

Company profile and research snapshot.

Company profile

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
CMPX recent ratings
DateFirmRatingTarget
Sep 23, 2026Craig-HallumBuy—
Sep 23, 2026CitizensMarket Outperform—
Sep 23, 2026GuggenheimBuy—
Sep 23, 2026WedbushNeutral—
Sep 23, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or death.Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate (DCR) was also significantly improved (62.2% vs. 36.8%).A new, post hoc analysis of overall survival (OS) included in the JCO publication uses the Two-Stage Estimation, an

Yahoo · Oct 14, 2026

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consists of non-qualified stock options to purch

Yahoo · Oct 14, 2026

Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns

The reset in analyst fair value estimates for Compass Therapeutics from about US$8.92 to roughly US$5.45 has become a key focus for investors trying to make sense of the recent price target cuts. Research commentary links these lower targets to a more cautious view on tovecimig’s regulatory path in biliary tract cancer, even as some analysts still point to the broader bispecifics pipeline and cash position as supports. As you read on, you will see how to track this evolving narrative and what...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By